Objective: Improving the way to establish the species belonging of muscle tissue fragments and particles using the quantitative solid-phase enzyme-linked immunosorbent assay method.
Material And Methods: We studied human muscle tissue fragments and particles (sampled 2-4 weeks before) and also dried extracts from the blood of certain animals, such as dogs, birds, pigs, and cats. The samples were studied using quantitative enzyme immunoassay with the domestic kit «IgG-total-ELISA-HEMA».
Objective: We investigated how different deceleration intentions (i.e. an automated vehicle either decelerated for leading traffic or yielded for pedestrians) and a novel (Slow Pulsing Light Band - SPLB) or familiar (Flashing Headlights - FH) external Human Machine Interface (eHMI) informed pedestrians' crossing behaviour.
View Article and Find Full Text PDFJ Phys Condens Matter
July 2024
Obtaining amorphous alloys with good mechanical and anticorrosion properties is an important problem of modern condensed matter physics. Since the preparation of amorphous alloys involves casting them from liquid state, information on the properties of the melts is needed. Viscosity is one of the most informative structure-sensitive property of melts.
View Article and Find Full Text PDFThe implementation of three-dimensional tissue engineering concurrently with stem cell technology holds great promise for in vitro research in pharmacology and toxicology and modeling cardiac diseases, particularly for rare genetic and pediatric diseases for which animal models, immortal cell lines, and biopsy samples are unavailable. It also allows for a rapid assessment of phenotype-genotype relationships and tissue response to pharmacological manipulation. Mutations in the and genes lead to dysfunctional mTOR signaling and cause tuberous sclerosis complex (TSC), a genetic disorder that affects multiple organ systems, principally the brain, heart, skin, and kidneys.
View Article and Find Full Text PDFThe global number of people with Alzheimer's disease (AD) doubles every 5 years. It has been established that unless an effective treatment for AD is found, the incidence of AD will triple by 2060. However, pharmacological therapies for AD have failed to show effectiveness and safety.
View Article and Find Full Text PDF